Roche Just Beat Both Rivals in the Biggest KRAS Showdown Yet
Roche's divarasib just beat both Amgen's sotorasib and BMS's adagrasib head-to-head in a Phase 3 lung cancer trial, hitting survival endpoints that could reshape KRAS G12C treatment. Wall Street is cautiously optimistic, but the real prize is still up for grabs.
The Fight Nobody Expected to Be So Decisive
For years, the KRAS G12C inhibitor market in lung cancer felt like a two-horse race. Amgen had sotorasib (Lumakras). Bristol Myers Squibb had adagrasib (Krazati). Both were good. Neither was great. And oncologists were left debating which "good enough" option to prescribe.
Then Roche walked into the ring and knocked both of them out at once.
Results from the Phase 3 Krascendo-1 trial, announced in early July, showed that Roche's divarasib beat both sotorasib and adagrasib head-to-head in previously treated KRAS G12C-mutant non-small cell lung cancer (NSCLC). The drug hit its primary endpoint of progression-free survival (how long patients lived without their cancer getting worse) and showed a statistically significant improvement in overall survival at an interim look. In a patient population with a grim prognosis, that's the kind of data that rewrites treatment guidelines.
What Krascendo-1 Actually Tested
This wasn't some clever cross-trial comparison where you squint at different datasets and hope the math holds up. Krascendo-1 was a direct, randomized, head-to-head brawl: 338 patients, split evenly between divarasib (taken once daily) and the doctor's choice of sotorasib (once daily) or adagrasib (twice daily).
The trial enrolled adults with advanced KRAS G12C-mutant NSCLC who had already been treated with other therapies. Tumor responses were measured by blinded independent reviewers, not the investigators running the trial, which adds a layer of credibility. Think of it as having a neutral referee instead of letting the coaches call fouls.
Roche hasn't released the specific numbers yet (hazard ratios, median survival times, and all the granular details are being saved for a medical conference). But the company confirmed that both the PFS and OS results were "clinically meaningful and statistically significant." In drug development, that's not marketing fluff. It means the difference was large enough and reliable enough to matter.
Why Divarasib Might Deserve the "Best-in-Class" Label
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
To understand why this matters, you need to know what KRAS G12C actually is. About 13% of lung adenocarcinomas carry this specific mutation, which acts like a stuck "on" switch for cell growth. First-generation drugs (sotorasib and adagrasib) can flip that switch off, but their grip isn't always tight enough or long enough.
Divarasib was designed to be different from the start. In preclinical testing, it showed 5 to 20 times greater potency and up to 50 times more selectivity than the first-gen drugs. Those lab advantages translated into impressive early clinical results: in Phase 1 data published in the New England Journal of Medicine, divarasib shrank tumors in roughly 53 to 56% of previously treated NSCLC patients, with responses lasting a median of about 14 months.
Now, with Krascendo-1, the lab promise has been validated in the gold-standard setting: a randomized Phase 3 trial against the actual competition. Not against placebo. Not against chemotherapy. Against the two drugs already approved for this exact use.
Roche's safety data looked clean, too. No new safety signals, and the side effects were described as manageable and reversible, consistent with everything seen in earlier trials.
Wall Street's Reaction: Impressed, Not Euphoric
Roche's stock bumped about 4% on the news, which in pharma land is a polite golf clap rather than a standing ovation. Why the restraint?
Jefferies analyst Michael Leuchten captured the mood perfectly, calling Krascendo-1 "a small win for Roche" while cautioning it's "premature to claim overall victory" in the KRAS space. His math: the second-line KRAS G12C NSCLC market is worth roughly CHF 1 to 2 billion, and about half of that is already baked into Roche's stock price.
The real prize, Leuchten argues, is first-line treatment, where the market could swell to CHF 5 billion. That's the difference between winning a regional tournament and taking home a Grand Slam. Divarasib's first-line data haven't read out yet, so the biggest question remains unanswered.
GlobalData oncology analyst Biswajit Podder was more bullish on the near-term implications, predicting that divarasib will "shift the later-line algorithm" and become the preferred targeted option, putting "meaningful pressure" on both Lumakras and Krazati.
The Competitive Fallout
This is where things get uncomfortable for Amgen and BMS.
Sotorasib was the first KRAS G12C inhibitor to market (FDA approval in 2021), but its early lead has been eroding. Adagrasib launched approximately 19 months after sotorasib, and has gained traction in part because of its ability to reach brain metastases. Both drugs have carved out footholds in colorectal cancer as well, giving them some diversification.
But in NSCLC, the core battlefield, a head-to-head loss on both PFS and OS is devastating. Oncologists, when given a choice, will almost always reach for the drug with superior survival data. If the full Krascendo-1 results hold up at a major conference presentation (expected soon), prescribers will have a hard time justifying sotorasib or adagrasib as their first pick.
Adding to the pressure: the broader KRAS G12C market is getting crowded. Four inhibitors are now approved globally (including two from Chinese manufacturers), with multiple additional programs in Phase 2 or 3. The segment could be worth nearly $10 billion by 2034, but only if you're the one patients and doctors choose.
The Bigger Picture: What Comes Next
Roche plans to submit the Krascendo-1 data to regulators and present the full results at an upcoming medical meeting. If approved, divarasib would likely become the new standard of care for previously treated KRAS G12C NSCLC, a population that desperately needs better options.
But the story doesn't end in second-line lung cancer. Roche is also testing divarasib in first-line NSCLC (the much larger market opportunity) and in combination with cetuximab for colorectal cancer, where the combo produced a 62% response rate in early data, nearly double what the drug achieved alone.
For patients, a more potent KRAS inhibitor with a clean safety profile is unambiguously good news. For investors, the calculus is more nuanced: divarasib strengthens Roche's oncology narrative, but the stock won't truly rerate until first-line data confirm whether this is a billion-dollar asset or a five-billion-dollar franchise.
For Amgen and BMS, the message is simpler. Their KRAS drugs just got benched by the new starter, and getting back on the court won't be easy.
Deals & M&A
4 min read
Big Pharma Can't Stop Shopping in China
Chinese biotech companies inked $110 billion in out-licensing deals in just six months, a record that puts 2026 on pace to demolish last year's total. Every major Western pharma company is now shopping in China, and the carts keep getting bigger.
